Erratum to : Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
Wong, Deborah J. L. (Department of Medicine. Division of Hematology-Oncology. University of California)
Robert, Lidia (Universitat Autònoma de Barcelona)
Atefi, Mohammad S. (Department of Medicine. Division of Hematology-Oncology. University of California)
Lassen, Amanda (Department of Medicine. Division of Hematology-Oncology. University of California)
Avarappatt, Geetha (University of Applied Sciences. Austria)
Cerniglia, Michael (Department of Medicine. Division of Hematology-Oncology. University of California)
Avramis, Earl (Department of Medicine. Division of Hematology-Oncology. University of California)
Tsoi, Jennifer (Department of Molecular and Medical Pharmacology. UCLA. USA)
Foulad, David (Department of Medicine. Division of Hematology-Oncology. University of California)
Graeber, Thomas G. (Department of Molecular and Medical Pharmacology. UCLA. USA)
Comin-Anduix, Begonya (Jonsson Comprehensive Cancer Center. UCLA. USA.)
Samatar, Ahmed (Discovery Oncology Merck Research Laboratories. Merck Research Laboratories. Boston. USA)
Lo, Roger S. (Department of Medicine. Division of Dermatology. UCLA. USA)
Ribas, Antoni (Jonsson Comprehensive Cancer Center. UCLA. USA)

Fecha:	2015
Resumen:	After publication of this work [1], we noted that we repeatedly had a typo mistake across the manuscript. The compound we used to test our cell lines was SCH772984 and not SCH722984. The typo was found misspelled in 54 occasions, including the title. We also wanted to add an affiliation detail to the author's list, as noted above. We regret the mistake and upload this note to clarify it.
Nota:	Correcció d'errades de l'article: Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma. Mol Cancer. 2014 (doi: 10.1186/1476-4598-13-194.)
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Publicado en:	Molecular cancer, Vol. 14 (July 2015) , ISSN 1476-4598

DOI: 10.1186/s12943-015-0393-2
PMID: 26134498

1 p, 297.1 KB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados